As of November 4, 2026, BioXcel Therapeutics, Inc. is a publicly traded company (OTC: BTAIQ); its largest reported holder is Integrated Core Strategies (US) LLC, with 8.4% on Schedule 13G/A of February 9, 2026. It and its subsidiaries filed for Chapter 11, as BioXcel Therapeutics, Inc. reported on Form 8-K on August 28, 2026 (Schedule 13G/A, February 9, 2026).
Is this your company?
About to sign with, pay or invest in BioXcel Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BioXcel Therapeutics, Inc. a real, registered company?
- BioXcel Therapeutics, Inc. files with the SEC under CIK 1720893 (its SEC filings).
- Its shares are listed under the ticker BTAIQ on OTC (SEC company record).
- Incorporated in Delaware; business address in New Haven, Connecticut, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court record: no federal case found under BioXcel Therapeutics, Inc. in our court records (as of 2026-11-04).
- Bankruptcy: BioXcel Therapeutics, Inc. and its subsidiaries filed for Chapter 11, as BioXcel Therapeutics, Inc. reported on Form 8-K on August 28, 2026 (Form 8-K, Item 1.03, filed 2026-08-28).
- Leadership changes: the latest reported is Samir Saleem, President (Form 8-K filed 2026-10-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-05-15).
Who are BioXcel Therapeutics, Inc.'s owners and officers?
BioXcel Therapeutics, Inc.: incorporated in Delaware; business address in New Haven, Connecticut; industry Pharmaceutical Preparations (Form D, 2026-10-30).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 7.05% |
| Schedule 13G/A, 2026-03-30 | Qatar Investment Authority | 0.6% |
| Schedule 13G/A, 2026-02-09 | Integrated Core Strategies (US) LLC | 8.4% |
| Schedule 13G, 2025-10-01 | Integrated Core Strategies (US) LLC | 5.2% |
Questions about who owns BioXcel Therapeutics, Inc.
Who owns BioXcel Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of BioXcel Therapeutics, Inc.: Integrated Core Strategies (US) LLC (8.4%, Schedule 13G/A, filed 2026-02-09).
When did Integrated Core Strategies (US) LLC buy into BioXcel Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Integrated Core Strategies (US) LLC on this page is the Schedule 13G, filed 2025-10-01, reporting 5.2%; its latest, Schedule 13G/A filed 2026-02-09, reports 8.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BioXcel Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BioXcel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioXcel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-30 | Samir Saleem | President | appointed | |
| Form 8-K, 2026-10-30 | Samir Saleem | appointed |
How much has BioXcel Therapeutics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-10-30).
What is BioXcel Therapeutics, Inc.'s court and legal record?
Bankruptcy or receivership reported on Form 8-K, Item 1.03: Form 8-K, 2026-08-28 (Chapter 11).
Red flags found
a bankruptcy or receivership filing by BioXcel Therapeutics, Inc. and its subsidiaries (Form 8-K, 2026-08-28).
Keep reading
More on BioXcel Therapeutics, Inc. and the records around it.
BioXcel Therapeutics, Inc. elsewhere on the record
- Leadership changes Oct 2026
- 5%+ stake filings Aug 2026
- Bankruptcy record
Companies that share a holder
- Qatar Investment Authority also filed stake reports on 9 other companies: Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026), West Bay BDC LLC (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: Fortress Biotech, Inc. (Oct 2026), Karyopharm Therapeutics Inc. (Oct 2026), Once Upon a Farm, PBC (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), Bluejay Diagnostics (Aug 2026)
Related pages
Bankruptcy filingsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bioxcel-therapeutics